. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. J Alzheimers Dis. 2013;33(4):929-39. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ42
(CSF)
MCI-AD
(26)
485 ± 93.5
pg/mL
ELISA;
AlzBio3;
Innogenetics
Petersen et al., 1999; McKhann et al., 1984
Aβ42
(CSF)
MCI-Stable
(51)
639.1 ± 255.3
pg/mL
ELISA;
AlzBio3;
Innogenetics
Petersen et al., 1999
tau-p181
(CSF)
MCI-AD
(26)
78.9 ± 26.1
pg/mL
ELISA;
AlzBio3;
Innogenetics
Petersen et al., 1999; McKhann et al., 1984
tau-p181
(CSF)
MCI-Stable
(51)
76.6 ± 69.3
pg/mL
ELISA;
AlzBio3;
Innogenetics
Petersen et al., 1999
tau-total
(CSF)
MCI-AD
(26)
488.5 ± 154.6
pg/mL
ELISA;
AlzBio3;
Innogenetics
Petersen et al., 1999; McKhann et al., 1984
tau-total
(CSF)
MCI-Stable
(51)
313.3 ± 145
pg/mL
ELISA;
AlzBio3;
Innogenetics
Petersen et al., 1999

Recommends

Please login to recommend the paper.

Comments

Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.